Bioventus06.07.17
Bioventus, a global provider of orthobiologics, has announced that, effective June 1, 2017, its full surgical orthobiologics portfolio is available through Premier Inc. Premier is a healthcare improvement company comprised of 3,750 U.S. hospitals and more than 130,000 other provider organizations throughout the country. Bioventus Surgical has numerous offerings for bone healing and spine fusion including allograft bone, synthetic bone graft substitutes and cell and marrow extraction needles.
OSTEOAMP, an allograft fusion solution, has been available through Premier since 2012. Additional products in the new agreement include: SIGNAFUSE, a bioactive bone graft substitute, EXPONENT demineralized bone matrix, PUREBONE demineralized cancellous bone and cancellous chips, INTERFACE bioactive bone graft, OSTEOMATRIX biphasic mineral/collagen bone graft, OSTEOPLUS biphasic mineral bone graft, CELLXTRACT, an autologous cell and marrow extraction device, and EXTRACTOR autologous cell and marrow extraction device.
“The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients, across a broad range of clinical situations, procedures, and costs,” said Henry Tung, MD, senior vice president, Bioventus and president, Bioventus Surgical. “We expect the Premier alliance of hospitals and healthcare providers to benefit greatly from our clinically supported and cost-effective orthobiologic solutions.”
OSTEOAMP, an allograft fusion solution, has been available through Premier since 2012. Additional products in the new agreement include: SIGNAFUSE, a bioactive bone graft substitute, EXPONENT demineralized bone matrix, PUREBONE demineralized cancellous bone and cancellous chips, INTERFACE bioactive bone graft, OSTEOMATRIX biphasic mineral/collagen bone graft, OSTEOPLUS biphasic mineral bone graft, CELLXTRACT, an autologous cell and marrow extraction device, and EXTRACTOR autologous cell and marrow extraction device.
“The Bioventus Surgical portfolio is designed to meet the needs of surgeons and their patients, across a broad range of clinical situations, procedures, and costs,” said Henry Tung, MD, senior vice president, Bioventus and president, Bioventus Surgical. “We expect the Premier alliance of hospitals and healthcare providers to benefit greatly from our clinically supported and cost-effective orthobiologic solutions.”